Company Description
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.
Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers.
The company was incorporated in 2015 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Walter Klemp |
Contact Details
Address: 5300 Memorial Drive, Suite 950 Houston, Texas 77007 United States | |
| Phone | (713) 300-5160 |
| Website | moleculin.com |
Stock Details
| Ticker Symbol | MBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659617 |
| CUSIP Number | 60855D200 |
| ISIN Number | US60855D2009 |
| Employer ID | 47-4671997 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Walter V. Klemp | Co-Founder, Chairman, President and Chief Executive Officer |
| Jonathan P. Foster CPA | Executive Vice President and Chief Financial Officer |
| Dr. Donald H. Picker Ph.D. | Chief Scientific Officer |
| Dr. Waldemar Priebe Ph.D. | Co-Founder, Founding Scientist and Chairman of Scientific Advisory Board |
| Dr. John Paul Waymack M.D., Sc.D. | Senior Chief Medical Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer of New Products |
| Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. | European Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 11, 2025 | 8-K | Current Report |
| Feb 11, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 10, 2025 | 8-K | Current Report |
| Feb 10, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 29, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 27, 2025 | 8-K/A | [Amend] Current report |
| Jan 27, 2025 | 8-K | Current Report |